English, Article edition: A Cost-Effectiveness Analysis of Fondaparinux Sodium Compared with Enoxaparin Sodium as Prophylaxis Against Venous Thromboembolism: Use in Patients Undergoing Major Orthopaedic Surgery Sean D. Sullivan; Bruce L. Davidson; Susan R. Kahn; ...

User activity

Share to:
 
Bookmark: http://trove.nla.gov.au/version/119862
Physical Description
  • article
Language
  • English

Edition details

Title
  • A Cost-Effectiveness Analysis of Fondaparinux Sodium Compared with Enoxaparin Sodium as Prophylaxis Against Venous Thromboembolism: Use in Patients Undergoing Major Orthopaedic Surgery
Author
  • Sean D. Sullivan
  • Bruce L. Davidson
  • Susan R. Kahn
  • James E. Muntz
  • Gerry Oster
  • Gary Raskob
Physical Description
  • article
Notes
  • Objective: To determine the cost effectiveness of fondaparinux sodium compared with enoxaparin sodium for prophylaxis against venous thromboembolism in patients undergoing major orthopaedic surgery. Methods: Using a cohort simulation model, two primary analyses were conducted from the perspective of the US healthcare payer. Probabilities for a trial-based analysis were obtained from patients participating in the fondaparinux clinical trial programme supplemented with data from published literature. Probabilities for a label-based analysis were estimated for a hypothetical cohort of US patients receiving either fondaparinux or enoxaparin as recommended by US FDA-approved labelling. Resource use and costs were obtained from large US healthcare databases. Outcome measures were rates of symptomatic thromboembolic events and healthcare costs. Costs were in 2003 values. Results: In the trial-based analysis, fondaparinux was estimated to prevent 15.1 symptomatic venous thromboembolic events (per 1000 patients) at 3 months for patients undergoing major orthopaedic surgery compared with enoxaparin. The cost savings (per patient) of using fondaparinux over enoxaparin are $US61 at 30 days, $US89 at 3 months, and $US155 at 5 years. In the label-based analysis, fondaparinux was estimated to prevent 17.8 venous thromboembolic events (per 1000 patients) at 3 months compared with enoxaparin, producing savings per patient of $US25 at discharge, $US112 over 1 month, $US141 over 3 months and $US234 over 5 years. Results remain robust to clinically plausible variation in input parameters and assumptions. Conclusion: Our model suggests that fondaparinux, when compared with the current standard regimen of enoxaparin for prophylaxis of venous thromboembolism in major orthopaedic surgery, improves outcomes and is cost saving from a US healthcare-payer perspective over the broad range of assumptions evaluated.
  • Cost-effectiveness, Enoxaparin-sodium, Fondaparinux-sodium, Low-molecular-weight-heparins, Venous-thrombosis
  • RePEc:wkh:phecon:v:22:y:2004:i:9:p:605-620
Language
  • English
Contributed by
OAIster

Get this edition

  • Set up My libraries

    How do I set up "My libraries"?

    In order to set up a list of libraries that you have access to, you must first login or sign up. Then set up a personal list of libraries from your profile page by clicking on your user name at the top right of any screen.

  • All (1)
  • Unknown (1)
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.

User activity


e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this edition

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this version

Add a comment